The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of treatment with the Ve-VRD or S-VRD (Venetoclax or Selinexor, plus Bortezomib, Lenalidomide and Dexamethasone) regimen in combination with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia. Patients with t(11;14) at diagnosis receive 3 cycles of induction therapy with Ve-VRD regimen and patients without t(11;14) with S-VRD regimen followed by the first infusion of CAR-T cells. Patients then received 3 cycles of Ve-VR or S-VR consolidation therapy, followed by ASCT and the second infusion of CAR-T cells. And VeR or SR maintenance starts on day 100 after ASCT.
This is a single-arm, open-label study to evaluate the efficacy and safety of Ve-VRD or S-VRD (Venetoclax or Selinexor, plus Bortezomib, Lenalidomide and Dexamethasone) regimen combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia.